Bionovo endocrine/metabolic news

Bionovo reduced headcount by over 90% to save cash. At Feb. 27, the company had 52 full-time employees. The remaining management said it will cease operations if sufficient funds are not received or if the company is not sold. Bionovo's Menerba, an estrogen receptor beta selective agonist, is in Phase III testing to treat hot flashes in postmenopausal women. The company said it is reviewing the trial, which started last October. Details were not disclosed (see BioCentury, Oct. 31, 2011). ...